Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02395744 · ClinicalTrials.gov registry record · NA
The COPPER-B Trial
A NA study, sponsored by Horizons International Peripheral Group.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT02395744 is a NA study that has completed, run by Horizons International Peripheral Group. The registered enrollment target is 11 participants.
The verdict
NCT02395744, a NA study, has completed, sponsored by Horizons International Peripheral Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of the COPPER - B study is to assess the feasibility, safety, and initial efficacy of paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC.
Interventions
- OTHER Paclitaxel administration using the OPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-03-11 |
| Est. Completion | 2017-02-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02395744
The ClinicalTrials.gov registry entry for NCT02395744 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Horizons International Peripheral Group, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel administration using the OPC is the first listed.
NCT02395744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02395744 about?
NCT02395744 is a clinical study titled "The COPPER-B Trial". The purpose of the COPPER - B study is to assess the feasibility, safety, and initial efficacy of paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC.
What is the current status of trial NCT02395744?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2015-03-11. Estimated completion is 2017-02-23.
What interventions are being tested in trial NCT02395744?
The interventions under investigation include: Paclitaxel administration using the OPC (OTHER).
Who is sponsoring clinical trial NCT02395744?
This trial is sponsored by Horizons International Peripheral Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.